Read the Journal of Managed Care + Specialty Pharmacy (JMCP) May 2025 Issue
AI can improve outcomes and efficiency, but payers need clear standards to ensure reliability, transparency, and equity. AMCP has launched initiatives focused on standards and best practices for AI, creating education, and fostering partnerships to guide responsible AI adoption.
Key takeaways from AMCP’s recent AI Preconference in Houston, Texas, where leaders in pharmacy, healthcare, technology, and policy gathered for a half-day of deep, engaging discussions at AMCP 2025.
ASAE awarded AMCP the 2025 Gold Circle Award in the Website category. The Gold Circle Awards competition is the premier association marketing, membership, and communications award that recognizes excellence, innovation, and achievement in association/nonprofit marketing, membership, and communications programs.
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
Thousands of managed care pharmacy professionals from health plans, PBMs, pharmaceutical manufacturers, and other managed care organizations convened in Houston, TX, from March 31–April 3 for AMCP 2025, the industry’s premier conference.
On April 16, 2025, the Centers for Medicare and Medicaid Services (CMS) issued guidance on CY 2026 Part D Formulary Submissions (Guidance). The Guidance includes important dates related to CY 2026 formulary submissions.
This month, the House and Senate reached an agreement on a concurrent budget resolution, after weeks of back-and-forth negotiations over topline spending and savings numbers.
On April 15, 2025, the Trump administration issued an Executive Order (EO) on prescription drug costs.
